EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)

ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma

Joyce F Liu iD, Nicoletta Colombo iD, Amit M Oza iD, Jean-Sebastien Frenel iD, Bradley R Corr iD, Maria M Rubinstein iD, Nicole S Nevadunsky, Stephanie Lheureux iD, Lydia Gaba iD, Lucía González Cortijo iD, Vanda Salutari iD, Benoit You iD und 7 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco-24-01606 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Joyce F Liu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Uterine Neoplasms, Neoplasm Recurrence, Local, Cystadenocarcinoma, Serous, Pyrimidinones. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE This phase IIb, single-arm, multicenter, global study (ADAGIO; ClinicalTrials.gov identifier: NCT04590248 ) assessed the efficacy and safety of adavosertib in patients with recurrent/persistent uterine serous carcinoma (USC) who had previously received platinum-based chemotherapy. METHODS Eligible patients were age 18 years and older and had histologically confirmed recurrent/persistent USC, previously treated with at least one platinum-based chemotherapy regimen, and with evidence of measurable disease. Adavosertib was administered orally at 300 mg once daily on days 1-5 and 8-12 of a 21-day cycle until discontinuation criteria were met. The primary end point was objective response rate (ORR) by blinded independent central review (BICR). Secondary end points included duration of response (DoR), progression-free survival (PFS), safety, and tolerability. Biomarkers previously associated with adavosertib response in other settings were assessed in archival tissue samples. RESULTS In 104 evaluable patients, one complete response and 26 partial responses were observed, for an ORR by BICR of 26.0% (95% CI, 17.9 to 35.5). Median DoR was 4.7 months (95% CI, 3.8 to 8.3); median PFS was 2.8 months (95% CI, 2.6 to 3.9). Biomarker analysis identified no single predictive alteration for adavosertib response, although a trend was observed for CCNE1 amplification or high cyclin E1 protein expression. Most patients (97.2%) experienced treatment-related adverse events (TRAEs), most frequently diarrhea (59.6%), nausea (59.6%), and anemia (58.7%). Grade ≥3 TRAEs occurred in 60.6% of patients, with neutropenia (21.1%) and fatigue (13.8%) most common. 17.4% of patients discontinued adavosertib due to AEs (treatment-related in 14.7%). CONCLUSION Adavosertib showed some antitumor activity in patients with recurrent/persistent USC. However, at 300 mg once daily dosing, it was not well tolerated in this population. Exploratory biomarker studies suggest CCNE1 /cyclin E1 expression may enrich for response to Wee1 inhibition in USC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine NeoplasmsNeoplasm Recurrence, LocalCystadenocarcinoma, SerousPyrimidinonesAntineoplastic AgentsHumansFemaleMiddle AgedAgedAdultProgression-Free SurvivalAged, 80 and overBiomarkers, TumorPyrazoles

Substanzen

adavosertibPyrimidinonesAntineoplastic AgentsBiomarkers, TumorPyrazoles

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Gynecologic Oncology Program, European Institute of Oncology, IRCCS, Milan, Italy.
  • Department of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Saint Herblain, and Nantes Université, Nantes, France.
  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado, Aurora, CO.

ORCID-Profile: Joyce F Liu, Nicoletta Colombo, Amit M Oza, Jean-Sebastien Frenel, Bradley R Corr, Maria M Rubinstein, Stephanie Lheureux, Lydia Gaba, Lucía González Cortijo, Vanda Salutari, Benoit You, Ana Oaknin

Zitieren

APA

Liu, J. F., Colombo, N., Oza, A. M., Frenel, J. S., Corr, B. R., Rubinstein, M. M., Nevadunsky, N. S., Lheureux, S., Gaba, L., González Cortijo, L., Salutari, V., You, B., Chiang, S., O'Connor, M. J., Oplustil O'Connor, L., Meulendijks, D., Khatun, M., Ghiorghiu, D., & Oaknin, A. (2025). ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-01606

Vancouver

Liu JF, Colombo N, Oza AM, Frenel JS, Corr BR, Rubinstein MM, et al. ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma. Journal of Clinical Oncology. 2025. doi:10.1200/jco-24-01606

BibTeX
@article{Liu2025,
  author = {Liu, Joyce F and Colombo, Nicoletta and Oza, Amit M and Frenel, Jean-Sebastien and Corr, Bradley R and Rubinstein, Maria M and Nevadunsky, Nicole S and Lheureux, Stephanie and Gaba, Lydia and González Cortijo, Lucía and Salutari, Vanda and You, Benoit and Chiang, Sarah and O'Connor, Mark J and Oplustil O'Connor, Lenka and Meulendijks, Didier and Khatun, Mahmuda and Ghiorghiu, Dana and Oaknin, Ana},
  title = {ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco-24-01606}
}
Kostenlos starten →